At week @ , virological suppression was achieved in @ patients ( @ % , @ % CI @-@ ) in the raltegravir @ mg group , @ patients ( @ % , @-@ ) in the raltegravir @ mg group , and @ patients ( @ % , @-@ ) in the efavirenz group .